675 related articles for article (PubMed ID: 26406377)
61. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.
Chipumuro E; Marco E; Christensen CL; Kwiatkowski N; Zhang T; Hatheway CM; Abraham BJ; Sharma B; Yeung C; Altabef A; Perez-Atayde A; Wong KK; Yuan GC; Gray NS; Young RA; George RE
Cell; 2014 Nov; 159(5):1126-1139. PubMed ID: 25416950
[TBL] [Abstract][Full Text] [Related]
62. Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells.
Kelso TW; Baumgart K; Eickhoff J; Albert T; Antrecht C; Lemcke S; Klebl B; Meisterernst M
Mol Cell Biol; 2014 Oct; 34(19):3675-88. PubMed ID: 25047832
[TBL] [Abstract][Full Text] [Related]
63. Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion.
Zarei M; Du H; Nassar AH; Yan RE; Giannikou K; Johnson SH; Lam HC; Henske EP; Wang Y; Zhang T; Asara J; Kwiatkowski DJ
J Exp Med; 2019 Nov; 216(11):2635-2652. PubMed ID: 31506280
[TBL] [Abstract][Full Text] [Related]
64. CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.
Bisteau X; Paternot S; Colleoni B; Ecker K; Coulonval K; De Groote P; Declercq W; Hengst L; Roger PP
PLoS Genet; 2013 May; 9(5):e1003546. PubMed ID: 23737759
[TBL] [Abstract][Full Text] [Related]
65. Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells.
Kavarthapu R; Dufau ML
Oncotarget; 2017 Apr; 8(16):27353-27363. PubMed ID: 28423697
[TBL] [Abstract][Full Text] [Related]
66. Suppression of Angiogenesis by Targeting Cyclin-Dependent Kinase 7 in Human Umbilical Vein Endothelial Cells and Renal Cell Carcinoma: An In Vitro and In Vivo Study.
Shi CS; Kuo KL; Chen MS; Chow PM; Liu SH; Chang YW; Lin WC; Liao SM; Hsu CH; Hsu FS; Chang HC; Huang KH
Cells; 2019 Nov; 8(11):. PubMed ID: 31752390
[TBL] [Abstract][Full Text] [Related]
67. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel.
Guo P; Yang J; Huang J; Auguste DT; Moses MA
Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18295-18303. PubMed ID: 31451668
[TBL] [Abstract][Full Text] [Related]
68. CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263.
Huang T; Ding X; Xu G; Chen G; Cao Y; Peng C; Shen S; Lv Y; Wang L; Zou X
Cell Death Dis; 2019 Aug; 10(8):602. PubMed ID: 31399555
[TBL] [Abstract][Full Text] [Related]
69. Secrets of a double agent: CDK7 in cell-cycle control and transcription.
Fisher RP
J Cell Sci; 2005 Nov; 118(Pt 22):5171-80. PubMed ID: 16280550
[TBL] [Abstract][Full Text] [Related]
70. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
[TBL] [Abstract][Full Text] [Related]
71. Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.
Caracciolo V; Laurenti G; Romano G; Carnevale V; Cimini AM; Crozier-Fitzgerald C; Gentile Warschauer E; Russo G; Giordano A
Cell Cycle; 2012 Mar; 11(6):1202-16. PubMed ID: 22391209
[TBL] [Abstract][Full Text] [Related]
72. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
[TBL] [Abstract][Full Text] [Related]
73. Is Cdk7/cyclin H/MAT1 the genuine cdk activating kinase in cycling Xenopus egg extracts?
Fesquet D; Morin N; Doree M; Devault A
Oncogene; 1997 Sep; 15(11):1303-7. PubMed ID: 9315098
[TBL] [Abstract][Full Text] [Related]
74. Discovery of SHR5428 as a selective and noncovalent inhibitor of CDK7.
Jia M; Wang W; Chen G; Wu T; Zhang T; Zhou Q; Yin J; Li J; Li X; Mao Y; Feng J; Hu M; Li X; He F
Bioorg Med Chem Lett; 2023 Sep; 93():129429. PubMed ID: 37543274
[TBL] [Abstract][Full Text] [Related]
75. Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype.
Olson CM; Liang Y; Leggett A; Park WD; Li L; Mills CE; Elsarrag SZ; Ficarro SB; Zhang T; Düster R; Geyer M; Sim T; Marto JA; Sorger PK; Westover KD; Lin CY; Kwiatkowski N; Gray NS
Cell Chem Biol; 2019 Jun; 26(6):792-803.e10. PubMed ID: 30905681
[TBL] [Abstract][Full Text] [Related]
76. An integrative multi-omics approach uncovers the regulatory role of CDK7 and CDK4 in autophagy activation induced by silica nanoparticles.
Ruan C; Wang C; Gong X; Zhang Y; Deng W; Zhou J; Huang D; Wang Z; Zhang Q; Guo A; Lu J; Gao J; Peng D; Xue Y
Autophagy; 2021 Jun; 17(6):1426-1447. PubMed ID: 32397800
[TBL] [Abstract][Full Text] [Related]
77. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
78. Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression.
Huang TT; Tseng LM; Chen JL; Chu PY; Lee CH; Huang CT; Wang WL; Lau KY; Tseng MF; Chang YY; Chiang TY; Ueng YF; Lee HC; Dai MS; Liu CY
EBioMedicine; 2020 Apr; 54():102717. PubMed ID: 32268268
[TBL] [Abstract][Full Text] [Related]
79. The cancer-testis gene,
Gu Y; Wang C; Zhu R; Yang J; Yuan W; Zhu Y; Zhou Y; Qin N; Shen H; Ma H; Wang H; Liu X; Hu Z
Cancer Biol Med; 2021 Feb; 18(1):74-87. PubMed ID: 33628586
[TBL] [Abstract][Full Text] [Related]
80. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.
D'Amato NC; Rogers TJ; Gordon MA; Greene LI; Cochrane DR; Spoelstra NS; Nemkov TG; D'Alessandro A; Hansen KC; Richer JK
Cancer Res; 2015 Nov; 75(21):4651-64. PubMed ID: 26363006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
